The absence of YTHDF1 in DC can enhance the cross-presentation of tumor antigens and the cross-priming of CD8+ T cells, thereby increasing the anti-tumor response of CD8+ T cells and enhancing the therapeutic effect of PD-L1 checkpoint blockade. The gene discussed is CD8A; the disease is neoplasm.